Standout Papers

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma 2007 2026 2013 2019 1.0k
  1. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma (2007)
    Meletios Α. Dimopoulos, Andrew Spencer et al. New England Journal of Medicine
  2. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma (2016)
    Antonio Palumbo, Asher Chanan‐Khan et al. New England Journal of Medicine
  3. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma (2011)
    David H. Henry, Luís Costa et al. Journal of Clinical Oncology

Immediate Impact

19 by Nobel laureates 20 from Science/Nature 98 standout
Sub-graph 1 of 20

Citing Papers

Small and long non-coding RNAs: Past, present, and future
2024 Standout
Theranostic Fluorescent Probes
2024 Standout

Works of Andrew Spencer being referenced

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
2014
The Developmental Timing Regulator AIN-1 Interacts with miRISCs and May Target the Argonaute Protein ALG-1 to Cytoplasmic P Bodies in C. elegans
2005

Author Peers

Author Last Decade Papers Cites
Andrew Spencer 7074 8231 5590 402 14.1k
Robert Z. Orlowski 9443 12960 8082 508 18.1k
Noopur Raje 10993 11796 9910 491 19.9k
William G. Bornmann 2675 7599 3571 167 14.5k
Bernard Klein 6537 7279 6285 387 17.1k
Rob Pieters 7793 9112 4063 515 22.3k
Leo Sachs 4344 12506 5900 396 22.4k
Edo Vellenga 8523 7534 5215 481 18.4k
R.J. Arceci 2994 5071 3514 389 12.3k
Olivier Bernard 5108 8599 3921 444 21.5k
Hubert Serve 6711 8347 3027 298 15.2k

All Works

Loading papers...

Rankless by CCL
2026